{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=ER+Positive&page=8",
    "query": {
      "condition": "ER Positive",
      "page": 8
    },
    "page_size": 10
  },
  "pagination": {
    "page": 8,
    "page_size": 10,
    "total_count": 418,
    "total_pages": 42,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=ER+Positive&page=9&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=ER+Positive&page=7&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-13T21:22:59.895Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05508906",
      "title": "Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Breast Cancer",
        "ER-positive Breast Cancer",
        "HER2-negative Breast Cancer",
        "Breast Cancer",
        "Locally Advanced Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Palazestrant",
          "type": "DRUG"
        },
        {
          "name": "Ribociclib",
          "type": "DRUG"
        },
        {
          "name": "Alpelisib",
          "type": "DRUG"
        },
        {
          "name": "Everolimus",
          "type": "DRUG"
        },
        {
          "name": "Atirmociclib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Olema Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 190,
      "start_date": "2022-08-31",
      "completion_date": "2028-01-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-15",
      "last_synced_at": "2026-11-13T21:22:59.895Z",
      "location_count": 14,
      "location_summary": "Gilbert, Arizona • San Francisco, California • Aurora, Colorado + 11 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05508906"
    },
    {
      "nct_id": "NCT00573755",
      "title": "Sorafenib and Letrozole, Anastrozole, or Exemestane in Treating Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Metastatic Breast Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "anastrozole",
          "type": "DRUG"
        },
        {
          "name": "exemestane",
          "type": "DRUG"
        },
        {
          "name": "letrozole",
          "type": "DRUG"
        },
        {
          "name": "sorafenib tosylate",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 120 Years · Female only"
      },
      "enrollment_count": 4,
      "start_date": "2007-12",
      "completion_date": "2013-04",
      "has_results": true,
      "last_update_posted_date": "2016-02-05",
      "last_synced_at": "2026-11-13T21:22:59.895Z",
      "location_count": 3,
      "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00573755"
    },
    {
      "nct_id": "NCT01463007",
      "title": "Partial Breast Irradiation Using Non Invasive Approach for Early Stage Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Accelerated partial breast irradiation",
          "type": "RADIATION"
        },
        {
          "name": "Extended Follow up",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "OTHER"
      ],
      "sponsor": "Jaroslaw Hepel",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "50 Years and older · Female only"
      },
      "enrollment_count": 40,
      "start_date": "2011-08",
      "completion_date": "2021-04-06",
      "has_results": true,
      "last_update_posted_date": "2021-05-19",
      "last_synced_at": "2026-11-13T21:22:59.895Z",
      "location_count": 4,
      "location_summary": "Lakeland, Florida • Providence, Rhode Island • Tacoma, Washington",
      "locations": [
        {
          "city": "Lakeland",
          "state": "Florida"
        },
        {
          "city": "Providence",
          "state": "Rhode Island"
        },
        {
          "city": "Providence",
          "state": "Rhode Island"
        },
        {
          "city": "Tacoma",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01463007"
    },
    {
      "nct_id": "NCT00283608",
      "title": "Pharmacogenetics of Anastrozole in Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Stage I, Stage II, or Stage III Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Single nucleotide polymorphism (SNP)",
          "type": "GENETIC"
        },
        {
          "name": "high performance liquid chromatography",
          "type": "OTHER"
        },
        {
          "name": "measurements by DXA",
          "type": "OTHER"
        },
        {
          "name": "questionnaire administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "GENETIC",
        "OTHER"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 1000,
      "start_date": "2005-07",
      "completion_date": "2010-03",
      "has_results": false,
      "last_update_posted_date": "2011-05-16",
      "last_synced_at": "2026-11-13T21:22:59.895Z",
      "location_count": 4,
      "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota + 1 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00283608"
    },
    {
      "nct_id": "NCT01750073",
      "title": "Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Estrogen Receptor Negative",
        "Estrogen Receptor Positive",
        "HER2/Neu Negative",
        "HER2/Neu Positive",
        "Invasive Breast Carcinoma",
        "Progesterone Receptor Negative",
        "Progesterone Receptor Positive",
        "Stage IA Breast Cancer",
        "Stage II Breast Cancer",
        "Stage IIA Breast Cancer",
        "Stage IIB Breast Cancer",
        "Stage III Breast Cancer",
        "Stage IIIA Breast Cancer",
        "Stage IIIB Breast Cancer",
        "Stage IIIC Breast Cancer",
        "Triple-Negative Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Therapeutic Conventional Surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "Trastuzumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "RADIATION",
        "PROCEDURE",
        "BIOLOGICAL"
      ],
      "sponsor": "University of Nebraska",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "19 Years and older · Female only"
      },
      "enrollment_count": 92,
      "start_date": "2012-12-07",
      "completion_date": "2025-11-24",
      "has_results": true,
      "last_update_posted_date": "2026-06-26",
      "last_synced_at": "2026-11-13T21:22:59.895Z",
      "location_count": 4,
      "location_summary": "Bellevue, Nebraska • Grand Island, Nebraska • Omaha, Nebraska",
      "locations": [
        {
          "city": "Bellevue",
          "state": "Nebraska"
        },
        {
          "city": "Grand Island",
          "state": "Nebraska"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01750073"
    },
    {
      "nct_id": "NCT03709082",
      "title": "Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "HER2-positive Breast Cancer",
        "Breast Cancer Metastatic"
      ],
      "interventions": [
        {
          "name": "Palbociclib 75mg",
          "type": "DRUG"
        },
        {
          "name": "Letrozole 2.5mg",
          "type": "DRUG"
        },
        {
          "name": "T-DM1",
          "type": "DRUG"
        },
        {
          "name": "Palbociclib 100mg",
          "type": "DRUG"
        },
        {
          "name": "Palbociclib 125mg",
          "type": "DRUG"
        },
        {
          "name": "Palbociclib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Kansas Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 3,
      "start_date": "2018-10-15",
      "completion_date": "2021-02-03",
      "has_results": false,
      "last_update_posted_date": "2024-03-05",
      "last_synced_at": "2026-11-13T21:22:59.895Z",
      "location_count": 5,
      "location_summary": "Kansas City, Kansas • Overland Park, Kansas • Kansas City, Missouri + 1 more",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Overland Park",
          "state": "Kansas"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        },
        {
          "city": "Lee's Summit",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03709082"
    },
    {
      "nct_id": "NCT02273973",
      "title": "A Study of Neoadjuvant Letrozole + Taselisib Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Letrozole",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Taselisib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 334,
      "start_date": "2014-11-12",
      "completion_date": "2017-03-13",
      "has_results": true,
      "last_update_posted_date": "2018-05-21",
      "last_synced_at": "2026-11-13T21:22:59.895Z",
      "location_count": 8,
      "location_summary": "Santa Ana, California • Boston, Massachusetts • Basking Ridge, New Jersey + 5 more",
      "locations": [
        {
          "city": "Santa Ana",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Basking Ridge",
          "state": "New Jersey"
        },
        {
          "city": "Commack",
          "state": "New York"
        },
        {
          "city": "Harrison",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02273973"
    },
    {
      "nct_id": "NCT03616587",
      "title": "Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "ER+ HER2- Advanced Breast Cancer"
      ],
      "interventions": [
        {
          "name": "AZD9833",
          "type": "DRUG"
        },
        {
          "name": "AZD9833 with palbociclib",
          "type": "DRUG"
        },
        {
          "name": "AZD9833 with everolimus",
          "type": "DRUG"
        },
        {
          "name": "AZD9833 with abemaciclib",
          "type": "DRUG"
        },
        {
          "name": "AZD9833 with capivasertib",
          "type": "DRUG"
        },
        {
          "name": "AZD9833 with ribociclib",
          "type": "DRUG"
        },
        {
          "name": "AZD9833 with anastrozole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 130 Years · Female only"
      },
      "enrollment_count": 396,
      "start_date": "2018-10-11",
      "completion_date": "2027-06-24",
      "has_results": false,
      "last_update_posted_date": "2026-08-18",
      "last_synced_at": "2026-11-13T21:22:59.895Z",
      "location_count": 5,
      "location_summary": "Aurora, Colorado • Sarasota, Florida • Philadelphia, Pennsylvania + 2 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03616587"
    },
    {
      "nct_id": "NCT00863655",
      "title": "Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Everolimus",
          "type": "DRUG"
        },
        {
          "name": "Exemestane",
          "type": "DRUG"
        },
        {
          "name": "Everolimus Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 724,
      "start_date": "2009-06-03",
      "completion_date": "2014-12-04",
      "has_results": true,
      "last_update_posted_date": "2017-05-02",
      "last_synced_at": "2026-11-13T21:22:59.895Z",
      "location_count": 63,
      "location_summary": "Chandler, Arizona • Fayetteville, Arkansas • Anaheim, California + 54 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00863655"
    },
    {
      "nct_id": "NCT03471663",
      "title": "A First-in-Human Study of D-0502 Alone and in Combination With Palbociclib in Women With Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "D-0502",
          "type": "DRUG"
        },
        {
          "name": "palbociclib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "InventisBio Co., Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 200,
      "start_date": "2018-03-18",
      "completion_date": "2023-10-18",
      "has_results": false,
      "last_update_posted_date": "2024-01-08",
      "last_synced_at": "2026-11-13T21:22:59.895Z",
      "location_count": 11,
      "location_summary": "Fresno, California • Aurora, Colorado • New Haven, Connecticut + 7 more",
      "locations": [
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Eugene",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03471663"
    }
  ]
}